Combined application of rapamycin and atorvastatin improves lipid metabolism in apolipoprotein E-deficient mice with chronic kidney disease

Atherosclerosis arising from the pro-inflammatory conditions associated with chronic kidney disease (CKD) increases major cardiovascular morbidity and mortality. Rapamycin (RAPA) is known to inhibit atherosclerosis under CKD and non-CKD conditions, but it can cause dyslipidemia; thus, the co-applica...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Eun Ju, Ahn, Sanghyun, Min, Seung-Kee, Ha, Jongwon, Oh, Goo Taeg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Biochemistry and Molecular Biology 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016660/
https://www.ncbi.nlm.nih.gov/pubmed/33050984
http://dx.doi.org/10.5483/BMBRep.2021.54.3.136

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016660/
https://www.ncbi.nlm.nih.gov/pubmed/33050984
http://dx.doi.org/10.5483/BMBRep.2021.54.3.136

Ejemplares similares